Back to top

Image: Bigstock

Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?

Read MoreHide Full Article

Key Takeaways

  • BSX cut its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18 amid headwinds.
  • WATCHMAN and EP organic sales fell 5.9% and 5.3%, respectively, amid demand and competitive pressures.
  • BSX's shares fell 53.5% YTD, while delayed product launches and elevated debt cloud its growth outlook.

Boston Scientific (BSX - Free Report) saw modest sales growth in the third quarter, with revenues climbing 1.5% year over year to $5.14 billion, though its adjusted earnings per share (“EPS”) dipped 2.7% to 73 cents year over year. Primarily due to unexpected headwinds within two high-growth franchises, WATCHMAN and Electrophysiology (“EP”), the company lowered its expectations for the rest of the year. It now projects full-year sales to grow about 4.25%, down from its previous forecast of 5.5-6.5% and expects full-year adjusted earnings to be between $3.16 and $3.18 per share, down from the previous estimate of $3.28 to $3.32.

However, the company continues to invest in its long-term growth drivers, which are fueled by a differentiated portfolio and strong pipeline of R&D. 

BSX’s Price Performance

Year to date, shares of the company declined 53.5% compared with the industry’s 15% decline. Meanwhile, the S&P composite rose 9.5%. The stock also underperformed its peers, Becton, Dickinson and Company (BDX - Free Report) and Edwards Lifesciences (EW - Free Report) , whose shares gained 12.3% and 25.7%, respectively.

 

Zacks Investment Research
Image Source: Zacks Investment Research

What’s Holding Back Boston Scientific?

WATCHMAN’s Sluggish Demand

Boston Scientific’s WATCHMAN franchise continues to face slowing demand as evolving clinical evidence affects patient identification and physician referrals. Organic sales in the third quarter of 2026 declined 5.9%, reversing 4% growth in the second quarter. U.S. sales fell approximately 7%, as standalone procedures declined at a high-teens rate. Meanwhile, concomitant procedure growth slowed to approximately 35% from more than 60% in the preceding quarter. The company expects standalone procedure trends to remain weak and concomitant growth to slow further in the fourth quarter. 

Global WATCHMAN sales are projected to decline at a low-single-digit rate sequentially during the period. It assumes no improvement in current market conditions during 2027. Despite increased physician education and commercial investment, patient referral trends have yet to recover. The next-generation WATCHMAN Elite platform is not expected until 2029, limiting near-term product catalysts. 

Competitive Pressure 

Boston Scientific faces increasing competition in U.S. electrophysiology as newer Pulsed Field Ablation (“PFA”) technologies gain market share. With PFA already accounting for approximately 80% of the U.S. atrial fibrillation market, further market conversion offers limited opportunities to offset share losses. In the third quarter of 2026, Electrophysiology organic sales declined 5.3%, reversing 9% growth in the second quarter. U.S. sales fell approximately 8%, while international growth slowed to 2%. The cybersecurity incident further accelerated competitive share shifts, and the company expects continued erosion until new technologies become available. 

Notably, the launch of FARAWAVE Ultra has been delayed from the second half of 2027 to early 2028, extending the period of competitive exposure. Cardiac Rhythm Management also remained weak, with third-quarter organic sales declining 1.6%, following a 2% decline in the preceding quarter. Low-voltage and high-voltage device sales continued to fall amid portfolio gaps. Delayed electrophysiology launches and persistent competitive threats could constrain growth until the broader product portfolio improves.

BSX Stock’s Valuation

From a valuation standpoint, Boston Scientific trades at 14.29X forward five-year earnings, below its median of 25.08X and the sector average of 17.66X.

 

Zacks Investment Research
Image Source: Zacks Investment Research

Meanwhile, peers, which include Becton, Dickinson and Company and Edwards Lifesciences, trade at higher forward earnings multiples of 16.36X and 31.94X, respectively.

Debt-Burden Balance Sheet

Boston Scientific’s balance sheet remains under pressure from elevated debt, acquisition spending and continued strategic investments. The company exited the third quarter of 2026 with cash and cash equivalents of $609 million, compared with $539 million at the end of the second quarter. Meanwhile, total debt was approximately $11.95 billion at the end of the third quarter of 2026, reflecting a gross debt leverage ratio of 1.9 times. 

Boston Scientific generated $867 million in free cash flow during the third quarter of 2026. The company also completed a $2-billion accelerated share repurchase and invested $1.5 billion in MiRus during 2026. Additionally, the pending Penumbra acquisition, expected to close in early 2027, adds further financing requirements. 

How BSX’s 2026 Estimates Look Now?

The Zacks Consensus Estimate for 2026 sales and loss per share implies a year-over-year improvement of 4.4% and 3.6%, respectively. The bottom-line estimates have moved south by 2.2% in the past 30 days.

 

Zacks Investment Research
Image Source: Zacks Investment Research

Our Take

Boston Scientific’s outlook remains weak as WATCHMAN demand slows and electrophysiology share losses deepen. The company expects little revenue and adjusted earnings growth in 2027, while key product launches have been shifted to 2028 and beyond. Also, reduced cash reserves relative to outstanding debt and continued acquisition spending could constrain financial flexibility and increase reliance on external financing. 

The stock’s recent performance has lagged its peers, while its estimates also appear to move south. Given all the challenges, existing BSX holders may find it prudent to exit their positions for now. 

Boston Scientific carries a Zacks Rank #5 (Strong Sell). 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in